vidually (4-9). Patients were defined as "responders" and in adult patients with acute respiratory distress syndrome (ARDS).
response (interindividual variation) as well as the tendency ratory distress syndrome; inhalation drug administration; dose-response of iNO to maintain or change its effect over time (intraindirelationship, drug vidual variation) were analyzed.
In adult patients with acute respiratory distress syndrome METHODS (ARDS) (1), the selective pulmonary vasodilation induced by inhaled nitric oxide (iNO) significantly reduces the pulmo- puterized NO application module (prototype of Servo 300; Siemens Elema, Solna, Sweden). Using NO gas cylinders with 100, 1,000, and 10,000 ppm, this system is able to deliver inspiratory NO concentrations from 10 parts per billion up to 100 ppm NO. Three times a day, as well as for all DR analysis measurements, inspiratory and expiratory NO concentrations were measured by a NO/nitric dioxide-specific chemiluminometer (Type AL 700; ECO Physics, Duernten, Switzerland) with a sensitivity up to 1 parts per billion. After inclusion of the patients and before starting continuous iNO treatment, an initial DR analysis was performed as already described (4) .
Primary endpoints of the study were the effect of 10 ppm iNO on oxygenation (Pa O 2 /Fi O 2 ) and mean pulmonary artery pressure (MPAP) with special regard to the changes over time, the effect on ventilator settings (Fi O 2 ) , and the time-dependent effect on the individual response established by repeated DR analyses during the study. Corresponding to former studies, patients were defined as "responders" when the improvement of Pa O 2 /Fi O 2 was 20% or more (3, 10, 11, (13) (14) (15) (16) . Secondary endpoints were the duration of ventilation, intensive care unit stay, and the use of ECMO therapy. It was hypothesized that long-term highdose (10 ppm) iNO therapy leads to altered individual DR characteristics during the treatment period.
Statistical Analysis
For description, all data are presented as median and range. A dosedependent effect of iNO on a measured parameter, expressed as the specific difference delta (⌬), was the difference between the iNO-induced change and the mean value from the baseline data before and after the measurement. DR curves were analyzed using a standardized, nonlinear goodness-of-fit model (Hill equation); p values are presented for tests between (unpaired data, two-sided Mann-Whitney U test) or within (paired data, two-sided Wilcoxon signed-rank test) the groups. The trial profile summarizes participant flow, timing of randomization, and treatment ( Figure 1) . No significant differences between the iNO group and the control group were found for age, addition, analysis of the Pa O 2 /Fi O 2 over time yielded a significant sex, the ARDS-inducing events, and previous history of intensive iNO effect only for the first day (data not shown). care unit stay or duration of mechanical ventilation (Table 1) . Furthermore, groups were comparable at inclusion regarding
RESULTS

Clinical Course
DR Analysis
ventilator parameters, hemodynamics, and gas exchange (Ta-
The dose-dependent effects of iNO on the cardiorespiratory ble 2). Weaning from iNO was possible in all patients from the parameters from both groups are indicated in Table 4 . The initial iNO group, and Fi O 2 was back at 0.4 after a total time of 2 to 6 DR curves for the systemic oxygenation and reduction of pulmohours from iNO withdrawal. nary hypertension were identical in both groups, demonstrating Analysis of the patients' outcome (regardless if for all or only a peak effect for oxygenation at 10 ppm iNO as described before for survivors) revealed no difference in respect of the overall (4). Another finding was that the time course of DR curves from duration of ventilation, intensive care unit stay, and the occurrence of additional organ failure (Table 3 ). The decision to establish ECMO was made by control of entry criteria under these conditions; that is, Pa O 2 values during NO inhalation were taken tor settings was registered in the following days ( Figure 2 ). In Definition of abbreviations: CI ϭ cardiac index; CVP ϭ central venous pressure; HR ϭ heart rate; iNO ϭ inhaled nitric oxide; MAP ϭ mean arterial pressure; MIP ϭ mean inspiratory pressure; MPAP ϭ mean pulmonary artery pressure; PCWP ϭ pulmonary capillary wedge pressure; PEEP ϭ positive end-expiratory pressure; PIP ϭ peak inspiratory pressure; Q VA /Q T ϭ venous admixture; RR ϭ respiration rate; SvO 2 ϭ mixed venous saturation; TV ϭ tidal volume.
Data are median (range).
the patients differed depending on the initial randomization: monary (sepsis, multiple trauma) ARDS patients. Finally, the correlation between the initial response (expressed as the perControl patients demonstrated similar DR characteristics over centage increase of Pa O 2 /Fi O 2 ) and the response after 2 days was time with a peak effect of iNO on systemic oxygenation at 10 ppm calculated. Comparing both groups, a significant correlation was NO throughout the study period ( Figure 3 , upper panel), alfound that is more pronounced in the iNO patients ( Figure 5 ). though the absolute effects were reduced on Days 2 and 4 comThis demonstrates that especially in the treatment group the pared with the initial data ( Table 4) . These findings are in accorintraindividual response varies only moderately with a tendency dance with already described data from former studies (4). The of increased sensitivity over time, that is, that the initial response mean effective dose (ED 50 ) for iNO (ppm) was estimated (nonof a patient is predictive for the following days ( 
Responders versus Nonresponders
4). Because of this phenomenon, the used iNO concentration of 10 ppm was no longer in the ideal range compared with the Analysis of the dose-dependent "response" versus "nonresponse" initial data and led to a decrease of Pa O 2 in some patients. For (3, 10, 11, 13-16) over time revealed no change over time in the the MPAP, the phenomenon of sensitization in the iNO group control group (data not shown), whereas an increased response is similar as for the Pa O 2 /Fi O 2 ; that is, a similar left shift of the to iNO at lower doses was registered in the treatment group MPAP DR curve was found for the treatment group (Figure 4) . after 4 days ( Figure 6 ). This effect was significant based on The differences in ED 50 , however, were less pronounced comPearson's chi-square test (p ϭ 0.0104). Interestingly, some papared with the oxygenation DR curves. Furthermore, we anatients, who initially were defined as responders at 10 and/or lyzed the response of Pa O 2 /Fi O 2 to iNO regarding the initial insult 100 ppm iNO, lost their response to iNO after a few days at ( Figure 5 ; discussed subsequently here). There were no differthese higher doses. In contrast, lower doses (0.1 or 1 ppm), which were not effective in the beginning of iNO treatment, now inences between pulmonary (pneumonia, aspiration) and nonpul- iNO (35-37). In conclusion, several pathways have been identified by which iNO affects its own effectiveness. Further experimental studies on chronic exposure to iNO are necessary to clarify the phenomenon of sensitization. duced a significant response, thus confirming that keeping an
This study does not demonstrate whether sensitization for initial iNO dose constant for long-term iNO therapy leads to iNO during long-term application is the only reason for the fact a phenomenon of overdosing with redeterioration of systemic that the beneficial effect (reduced Fi O 2 ) disappears after 24 hours. oxygenation.
Lum and colleagues found that as a common environmental air pollutant NO contaminates the hospital compressed air, which is also used for mechanical ventilators. As an "occult NO inhala-
DISCUSSION
tion," even these low doses of NO ranging from 0.013 to 0.079 Repeated analysis of DR curves in patients receiving 10 ppm ppm significantly improve oxygenation during ARDS treatment iNO revealed that continuous inhalation of NO leads to a left (38) . This means that a decreasing Fi O 2 (i.e., an increasing fraction shift of the DR curve for both oxygenation and pulmonary vascuof compressed air) is paralleled by an increased inspiratory fraclar resistance. This corresponds to a sensitization to lower iNO tion of occult NO. Hence, the control group might not be a real doses. As a consequence, the number of responders to low iNO "placebo" group. This could be another reason why differences doses increased, whereas some patients became nonresponders to the iNO group disappear when patients improve. The absence to higher doses. The data confirmed previous results (13-16) that of a beneficial effect within the iNO group is obviously not based a reduction of Fi O 2 as clinical benefit of iNO was found only on a tachyphylaxis, that is, a reduced sensitivity after long-term within the first 24 hours. Nevertheless, there was a reduced reiNO, as was postulated by Cornfield and colleagues, who investiquirement for ECMO treatment in patients from the iNO treatgated the effect of a pretreatment with low-dose iNO before ment group. Finally, iNO effects on oxygenation were not differstarting a continuous high-dose iNO therapy in newborns with ent between pulmonary and extrapulmonary ARDS. pulmonary hypertension (39). As described in previous studies To the best of our knowledge, the study presented here is (13-16), we also found a significant difference of Fi O 2 between the first randomized, controlled trial that analyzes the timethe groups only within the first 24 hours. The increased sensitivity dependent changes of iNO DR in patients with ARDS. The for iNO in the treatment group as described previously here is peak effect of iNO on oxygenation seems to contrast with that not contradictory to this phenomenon, as DR analyses (Figures reported in previous studies, which mostly revealed a plateau 3 and 4) are intraindividual comparisons, whereas the difference effect with no further changes at higher iNO doses (6-9, 18).
in Fi O 2 ( Figure 2 ) is interindividual. In other words, patients from These conclusions were drawn because absolute differences bethe iNO group, in contrast to the control patients, may have a tween Pa O 2 /Fi O 2 values at higher compared with lower doses were significant difference in oxygenation when 10 ppm iNO is tested not significant (7). This is not the case when DR curves are versus 0 ppm (on-off measurements, see the online supplement). calculated considering relative changes (4). However, the quesThe clinical effectiveness, however, is dependent from the situation as to why oxygenation redeteriorates at higher iNO doses tion during continuous ventilation: When the Pa O 2 /Fi O 2 of the remains unanswered. The hypothesis that NO reaches only ventiiNO patients receiving 10 ppm iNO is not different from the Pa O 2 / lated areas and gives rise to a selective pulmonary vasodilation Fi O 2 of the control patients without iNO, there is no difference in has to be discussed, as meanwhile there is evidence that the Fi O 2 , regardless the intraindividual effects. This was indeed the bioactive form of NO is transported in plasma without being case in the presented study, as demonstrated by daily on-off inactivated, thereby eliciting effects beyond the pulmonary circumeasurements (see the online supplement). lation (19) . This could be the reason that iNO is transported in Some aspects of the study protocol remain to be discussed. the vascular bed, especially at higher doses, thus contributing to
The trial was planned and conducted based on an "intent-tothe dilation of the downstream vasculature (19, 20) . By this mechatreat" protocol, that is, without individual amendments. This nism, high-dose iNO might induce similar effects to those of sysincluded a continuous application of 10 ppm iNO during the DR temic vasodilators, which were found to worsen oxygenation.
analysis period, that is, at least for 96 hours. It might be argued It was found that the application of external iNO inhibits that iNO doses should have been reduced after patients were endogenous NO synthesis in the pulmonary capillaries (21). Inhisensitized. Before analysis of the DR data from 20 patients per bition of endogenous NO synthases again increases the response group, however, this effect could not be foreseen. As a consequence for future studies, a modified protocol using individual to iNO (22), which has to be considered as a possible pathomech- iNO titration seems to be reasonable. Furthermore, the inclusion of patients was not dependent on a previous positive response to iNO, which might be criticized for ethical reasons. The main inclusion criterion was severe ARDS (as defined by the protocol), that is, a state when application of iNO for therapy may be taken into consideration by the physician. Determining the number of responders over time, however, is important to assess the effectiveness of a drug and was therefore used as a parameter indicating the overall response of patients to iNO. As demonstrated, this number of responders was increased by previous iNO treatment, especially for low doses. Finally, a clear definition of "response" to iNO is still missing. We used a 20% threshold for improvement of the Pa O 2 /Fi O 2 , as suggested by several investigators to allow a better comparability with previous results. This ARDS. In our study, we analyzed the response, that is, "the
